Heart procedure to close an atrial clot risk pouch in kidney failure
Part of Heart & circulation, Kidney & urinary clinical trials.
This trial tests a heart procedure that closes a part of the heart called the left atrial appendage to help prevent stroke in people with an irregular heartbeat (atrial fibrillation) and very advanced kidney disease. It’s mainly for patients who can take the needed blood-thinner medicines and who do not already have a clot in that pouch.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- A doctor has diagnosed atrial fibrillation that is not related to heart valve disease
- Your stroke risk is high enough (CHA2DS2-VASc score 2 or more)
- Your kidney function is very low (KDOQI stage 5, eGFR under 15), with or without dialysis
- You can legally and safely take aspirin and/or clopidogrel (no absolute allergy/contraindication)
- There is no clot inside the left atrial appendage found on screening tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a procedure called left atrial appendage occlusion. It blocks off a small pouch in the heart where blood clots can form, to reduce stroke risk without needing long-term blood thinners. This might help kidney dialysis patients who have atrial fibrillation, even though they are on dialysis.
This study tests a device and procedure to close off a small pouch in the heart (left atrial appendage) where blood clots can form in people with atrial fibrillation. The goal is to reduce the risk of stroke, possibly lowering the need for long-term blood thinners.
This trial tests a procedure to close off a small pouch in the heart called the left atrial appendage, which is a common source of blood clots in people with atrial fibrillation. The goal is to lower your stroke risk without needing to take blood thinners long-term.
This trial tests the Zenith system, a device that seals off a heart area called the left atrial appendage to reduce stroke risk in people with atrial fibrillation (AF). You may be eligible if you have AF and a doctor recommends LAA closure, and you can return for follow-up scans and visits.
This study compares a procedure to close a small pouch in the heart (which is a common source of blood clots causing stroke) to using medications alone in people with atrial fibrillation who cannot safely take blood thinners. The goal is to see if this procedure can reduce stroke risk without the bleeding risks of long-term blood thinners.
This study tests whether closing a heart pocket called the left atrial appendage can lower future stroke or other clot-related events in people with atrial fibrillation. It’s mainly for people who have had a prior clot-related event or are at higher risk but may not be good candidates for long-term blood thinners.
Hear when a new Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.